About Abcellera Biologics
Abcellera Biologics is a publicly listed company based in Vancouver (Canada) founded in 2012. An AI-enabled platform is used for antibody discovery. Abcellera Biologics has raised $115.05 million across 5 funding rounds from investors including Lilly, Orbimed and Canadian Space Agency. The company has 596 employees. Abcellera Biologics has completed 1 acquisition, including Trianni. Its website abcellera.com draws about 30 thousand monthly visits. Abcellera Biologics offers products and services including Antibody Platforms and T-Cell Engagers. Its focus areas include Life Sciences, Dermatology, Drugs and Eczema. Its legal entity is ABCELLERA BIOLOGICS INC.
Company details
AbCellera Biologics was founded in 2012 in Vancouver, Canada, within the biotechnology sector. Antibody discovery is facilitated through an AI-enabled platform that includes Celium, a visualization software, and proprietary microfluidic single-cell assays for screening. Repertoire sequencing technologies are combined with functional data from single B cells to annotate immune repertoires. A proprietary humanized mouse platform is also employed for developing humanized antibodies.
- Headquarters Vancouver, Canada
- Employees 596
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abcellera.com
- Social LinkedIn X
- Legal Name Abcellera Biologics Inc.
Products & Services of Abcellera Biologics
Abcellera Biologics offers a comprehensive portfolio of products and services, including Antibody Platforms and T-Cell Engagers.
Platforms for developing differentiated antibody therapies.
Solutions for targeted cancer treatments using bispecific antibodies.
Funding Insights of Abcellera Biologics
Abcellera Biologics has successfully raised a total of $115.05M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115.05M
- Total Rounds 5
- First Round $50,000
(Mar 2018)
- Investors Count 9
All 5 funding rounds of Abcellera Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
9 investors in total: 8 institutional and 1 angel.
Investors in Abcellera Biologics
Abcellera Biologics has secured backing from 9 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, Orbimed and Canadian Space Agency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on multiple sectors | dcvc.com | Palo Alto, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Venture capital fund backed by the Christian family office | presight.vc | West Hollywood, United States | ||
Canadian space agency focused on social and economic benefits | 1989 | asc-csa.gc.ca | Longueuil, Canada | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Higher education and research are provided by the University of Minnesota Twin Cities. | umn.edu | Minneapolis, United States | ||
PT Peter Thiel | Co-founder of PayPal, early Facebook investor, influential tech angel investor | unknown_9394aca697d7471fa |
Investor details for Abcellera Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abcellera Biologics
172 people are tracked at Abcellera Biologics (44 in leadership, 4 in board & advisors, 124 in team); the tracked headcount is 596.
| Name | Role | Group |
|---|---|---|
Aaron J Mitchell | People Partner | Leadership |
Stephanie Masterman | Director, Discovery & Development Project Management | Leadership |
Shawn Lai | Senior Director, Specialized Finance | Leadership |
Anne Stevens | VP, Business Development | Leadership |
Graham Craig | Director, Corporate Development | Leadership |
Kush Dalal | Director, Biochemistry | Leadership |
Emilie Lameignere | Associate Director, High-Throughput Antibody Assessment | Leadership |
Alessandra Smith | Head, FP&A | Leadership |
Andrea Stewart | Director, Strategic Marketing, Business Development | Leadership |
Véronique Lecault | Director & COO | Leadership |
Andrew Booth | CFO | Leadership |
Carl Hansen | Chairman, CEO & President | Leadership |
Srinivasa Pothula | Associate Director, Operations | Leadership |
Lindsay Devorkin | Associate Scientific Director | Leadership |
Tim Jacobs | Director, Molecular Design & Engineering | Leadership |
Martin Hogan | Senior Director, Strategic Finance | Leadership |
Marcie Thiessen | Senior Director, Finance & Accounting | Leadership |
Tatiana Solis | People Partner | Leadership |
Tiffany Chiu | VP, Communications | Leadership |
Kevin O'Brien | Chief Financial Officer | Leadership |
152 more people are available in the full profile.
Complete people profiles for Abcellera Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Abcellera Biologics
Abcellera Biologics is a publicly listed company on the NASDAQ with ticker symbol ABCL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Dec 2020
- Listed onNASDAQ: ABCL
- Listed entityAbCellera Biologics Inc.
- Exchange sectorHealth technology
- ISINCA00288U1066
- Share price$12.61 (-0.2% on the day) · 2026-10-13
- Market capitalisation$4.09B
- EPS (diluted, trailing year)$-0.54
- Volume (last session)3,254,184
Financials of Abcellera Biologics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $75.1M | -$146.4M | -$188.3M |
| 2024 | $28.8M | -$162.9M | -$217.8M |
| 2023 | $38.0M | -$146.4M | -$206.3M |
| 2022 | $485.4M | $158.5M | $316.1M |
| 2021 | $375.2M | $153.5M | $267.2M |
Detailed financial statements for Abcellera Biologics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abcellera Biologics
Abcellera Biologics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Trianni.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Transgenic mouse platform is utilized for fully human antibody discovery. | trianni.com | San Francisco, United States | 2010 | Nov 2020 | $90M |
Complete acquisition details for Abcellera Biologics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abcellera Biologics
5 dated milestones of Abcellera Biologics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Abcellera Biologics is founded.
- Funding First funding round of $50K.
- Acquisition Acquires Trianni.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Web traffic of Abcellera Biologics
The website of Abcellera Biologics (abcellera.com) receives about 29.9K visits a month.
- Monthly visits29.9K
▲ 10.6% vs previous month
Websites whose visitors overlap most with Abcellera Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aspectbiosystems.com | 100% | 17.8K | #1,378,457 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abcellera Biologics
Complete news archive for Abcellera Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abcellera Biologics
Abcellera Biologics was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Abcellera Biologics is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Abcellera Biologics is a funded company, having raised a total of $115.05M across 5 funding rounds to date. The company's 1st funding round was a Seed of $50K, raised on Mar 2018.
Abcellera Biologics has 596 employees.
Annual revenue of Abcellera Biologics is $75.13M as on Dec 31, 2025.
AbCellera Biologics was founded in 2012 in Vancouver, Canada, within the biotechnology sector. Antibody discovery is facilitated through an AI-enabled platform that includes Celium, a visualization software, and proprietary microfluidic single-cell assays for screening. Repertoire sequencing technologies are combined with functional data from single B cells to annotate immune repertoires. A proprietary humanized mouse platform is also employed for developing humanized antibodies.
Abcellera Biologics offers Antibody Platforms and T-Cell Engagers.
Yes, Abcellera Biologics is publicly traded on NASDAQ under the ticker symbol ABCL.
Abcellera Biologics has made 1 acquisition, including Trianni.
Abcellera Biologics has 9 investors. Key investors include Lilly, Orbimed, Canadian Space Agency, DCVC, and Viking Global Investors.
Abcellera Biologics operates through Abcellera Biologics Inc..